What question did this study set out to answer?

To evaluate the clinical performance of an IGF1 LC-MS/MS assay and its normative dataset.

March 2, 2026

Clinical performance of an IGF1 LC-MS/MS assay and associated normative dataset in routine endocrinology.

Key Points

To evaluate the clinical performance of an IGF1 LC-MS/MS assay and its normative dataset.
Utilized a population-based normative dataset for IGF1 levels.
Compared results with traditional ligand-binding assay (LBA) methods.
Conducted clinical assessments to determine alignment of results.
Demonstrated superior alignment of the LC-MS/MS assay with clinical assessments over LBA.
Established the IGF1 method as a reliable benchmark for IGF1 interpretation.
Facilitated the potential for broader adoption of the Lifelines normative dataset.

Abstract

Our LC-MS/MS IGF1 assay integrated with its own population-based normative dataset demonstrated superior alignment with clinical assessment compared with LBA results. In our setting, this method provides a clinically reliable benchmark for IGF1 interpretation and may serve as a reference for IGF1 harmonization and broader adoption of the Lifelines normative dataset in routine endocrinology.

Bookmark

Clinical performance of an IGF1 LC-MS/MS assay and associated normative dataset in routine endocrinology.

Key Points

Abstract

Cite This Study